Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in NAFLD and NASH
NCT02009592Completed
- Sponsor
- Bezmialem Vakif University
- Start
- Jun 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rifaximin in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Bezmialem Vakif University. Primary endpoints: Pro-inflammatory and anti-inflammatory cytokine levels at 1 month, Serum endotoxin levels at 1 month and 1 more. Started Jun 2013; status: completed.
02
Drugs
rifaximin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02009592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009592.